ARTICLE | Finance
Regulatory nightmare
April 7, 2008 7:00 AM UTC
1Q Stock Wrap-Up
While the general market downturn was the obvious cause of across-the-board losses in biotech last quarter, the regulatory environment was at the fore when it came to stocks that took big hits. Indeed, adverse regulatory news events exceeded the number of late-stage clinical blow-ups (see "Approvals & Setbacks" A13). ...